Noranelle (Ethinylestradiol, Levonorgestrel)

Ethinyloestradiol, the estrogen component, binds to estrogen receptors and contributes to suppression of the hypothalamic‑pituitary‑gonadal axis. Together with levonorgestrel, it prevents the mid‑cycle surge of luteinizing hormone, thereby inhibiting ovulation, and helps create a cervical mucus environment that is hostile to sperm.

The dosing regimen for Noranelle is determined by the prescribing healthcare professional. Typically, the product is taken as one tablet daily at the same time each day, following the specific pack instructions provided by the prescriber.

Noranelle is intended for use only when pregnancy is not desired. It should not be started during an existing pregnancy, and women who become pregnant while taking it should discontinue use and seek medical advice. Limited data are available on safety during breastfeeding; clinicians usually recommend alternative contraception for nursing mothers.

To order Noranelle, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any required temperature control) and the necessary import documentation.

Noranelle contains the standard dose combination of ethinyloestradiol and levonorgestrel, which is comparable to many other second‑generation combined oral contraceptives. Its efficacy, safety profile, and side‑effect spectrum are similar to other products in the same class, though individual tolerability may vary based on patient‑specific factors such as hormone sensitivity or metabolic interactions.

Noranelle tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack to protect them from moisture and light. Keep the product out of reach of children and do not use tablets that appear discoloured or damaged.

Noranelle is taken orally, usually as a single tablet each day. It is important to take the tablet at the same time each day to maintain consistent hormone levels. If a dose is missed, follow the specific instructions provided in the patient information leaflet or consult a healthcare professional.

Serious but rare risks include venous thromboembolism, pulmonary embolism, stroke, myocardial infarction, severe allergic reactions, and liver tumors. Women with a history of clotting disorders, smoking over age 35, uncontrolled hypertension, or estrogen‑dependent cancers are at higher risk and should avoid using Noranelle.

Noranelle is contraindicated in women with known or suspected pregnancy, active or past venous thromboembolism, estrogen‑dependent tumors, uncontrolled hypertension, severe liver disease, or unexplained vaginal bleeding. It should also be avoided by smokers aged 35 years or older and by anyone taking strong CYP3A4‑inducing medications without appropriate medical guidance.